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SSTR2 promoter hypermethylation is
associated with the risk and progression of
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Abstract
Background: Somatostatin receptor 2 (SSTR2) encodes somatostatin receptor that can inhibit the cell proliferation
of solid tumors. Promoter hypermethylation is likely to silence the expression of SSTR2. The goal of our study was to
investigate the association between SSTR2 promoter methylation and the risk and progression of laryngeal
carcinoma.
Methods: In the current study, tumor tissues and their adjacent non-tumor tissues were collected from a total of
87 laryngeal squamous cell carcinoma (LSCC) male patients. DNA methylation levels of nine SSTR2 promoter CpGs
were measured using the bisulphite pyrosequencing technology.
Results: Our results revealed that there was a significantly increased SSTR2 promoter methylation in LSCC
tissues than in their adjacent non-cancerous tissues (adjusted P = 0.003). Breakdown analysis by age indicated
that the significant association was mainly contributed by patients younger than 60 (adjusted P = 0.039) but
not in patients older than 60. Meanwhile, the significant association was observed in the patients with
moderately (adjusted P = 0.037) and well differentiated tissues (adjusted P = 0.028), as well as the patients with
histological stage IV (adjusted P = 0.031). Multivariate Cox analysis suggested that SSTR2 promoter methylation
was an independent prognostic factor of LSCC (HR = 1.127, 95 % CI = 1.034–1.228).
Conclusions: In conclusion, SSTR2 promoter hypermethylation might be associated with the risk and
progression of LSCC in males.
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Background
Laryngeal cancer is a devastating malignancy of head
and neck, and its incidence and mortality rates are in-
creasing recently [1]. Despite improvement of onco-
logical and surgical treatments over the last 20 years, 5-
year survival rates of laryngeal cancer remained poor
since the middle of 1980s [2, 3]. More than 90 % of la-
ryngeal cancer has been pathologically identified as la-
ryngeal squamous cell carcinoma (LSCC) [1]. According
to the Cancer Facts & Figures 2015 data, the majority of
laryngeal cancer patients are males.
Currently, total laryngectomy and postoperative
radiotherapy are the most common treatments for
LSCC [4]. Due to serious impairment in laryngeal
function and low quality life that brings for patients,
the exact molecular pathogenesis of LSCC is still ur-
gently needed to be explored. It is hypothesized that
LSCC may result from the interactions of many
complex factors, including environmental factors
(smoking, alcohol consumption, air pollution, and in-
fection) and genetic factors [5]. Meanwhile, accumu-
lating studies suggest that there are numerous
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aberrant epigenetic modifications in laryngeal cancer
[6].
Somatostatin (SST) is an important peptide in the
regulation of cell secretion and proliferation [7]. It
operates through engagement on a family of 5 trans-
membrane G-protein coupled somatostatin receptors
(SSTRs 1–5) [8]. Somatostatins have a function of
anti-proliferation, pro-apoptosis and anti-migration,
and thus play a role in the suppression of tumor
growth. Hypermethylation of SSTR1 gene along with
reduced expression was found in head and neck squa-
mous cell carcinoma [9], and the reversed SSTR5
methylation was shown to up-regulate SSTR5 mRNA
expression in prostate cancer [10]. SSTR2 is widely
distributed and it is responsible for the anti-
proliferative effect of somatostatin and its analogs
in vitro and in vivo [11]. SSTR2 protein levels were
significantly lower in the malignant larynx than the
pre-malignant larynx [12]. However, there was a lack
of association study between SSTR2 methylation and
laryngeal cancer.
Epigenetic modifications are crucial for tumorigen-
esis [13]. In mammalian cells, DNA methylation, as
one of the most common modifications, occurs
mainly at the C5 position of cytosine-phosphate-
guanine (CpG) dinucleotides [14]. Genes with aber-
rant DNA methylation have been shown with great
potential in the early detection and prognosis of can-
cers [15–18]. In light of previous findings, we aimed
to test whether SSTR2 promoter methylation contrib-
uted to the pathogenesis of laryngeal cancer.
Methods
Tissues samples
All the tumors and their paired adjacent non-tumor tissues
were collected from 87 male patients ranging from 40 to
86 years old. All the tissues were postoperative laryngeal
specimens obtained from the LSCC male patients.
There were 73 smokers and 14 non-smokers. And
there were 40 well differentiated cases (Figures 1a
and n), 32 moderately differentiated cases, and 15
poorly differentiated cases (Figures 1c and D) accord-
ing to their pathologic diagnoses. And there were 25
stage I, 14 stage II, 10 stage III, and 38 stage IV pa-
tients. There were 43 cases aged younger than
60 years, 33 cases aged 60–70 years, and 11 cases
aged older than 70 years. Overall survival (OS) data
was recorded from 54 out of 87 patients between
June 2010 and August 2015. The controls were the
non-cancerous adjacent tissues that were obtained
from at least 5 cm outside the edge of tumors, al-
though they might not accurately represent non-
cancerous control tissues. Generally, total laryngec-
tomy is the most common treatment for laryngeal
cancer patients. Moreover, surgery-only laryngeal
cancer patients had significantly better survival than
those with radiotherapy or chemotherapy [19]. In
addition, chemoradiotherapy was shown to affect the
DNA methylation level [20]. Therefore, we excluded
the patients with radiotherapy or chemotherapy in
our study. All the specimens were obtained fresh
and stored at −80 °C. None of the patients had a
history of hereditary cancer. All the participants in
Fig. 1 Histopathology of test specimens. a Well differentiated tumor tissues of LSCC (x200). b Well differentiated non-tumor tissues of LSCC
(x200). c Poorly differentiated tumor tissues of LSCC (x200). d Poorly differentiated non-tumor tissues of LSCC (x200)
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the study have signed the informed consent forms.
Permission was also obtained from the local ethics
committee to access the pathology archives at De-
partment of Otolaryngology at Ningbo Lihuili Hos-
pital, Ningbo, Zhejiang, China.
Bisulfite pyrosequencing methylation assay and primer
sequences
Genomic DNA extraction from tumor samples and sub-
sequent quantification procedures were as described be-
fore [21]. The details of DNA bisulfite conversion were
as described previously [21]. The sequences were 5’-
AGGGTAGAGGAGTTAGGAATTT-3’ for the forward
primer, 5’-Biotin-ACCCCTCACCTTTACTTTTC-3’ for
the reverse primer, and 5’-ACCCAACCACTATCCC-3’
for the sequencing primer.
Statistical analyses
Statistical analyses were performed using SPSS v18.0
(SPSS Inc., Chicago, IL). Data was expressed as mean ±
standard deviation (SD). Analysis of variance (ANOVA)
was used to evaluate the association between the risk
factors (including age, smoking behavior, histological dif-
ferentiation and clinical stage) and their relative methy-
lation rate difference. Paired sample T-test and non-
parametric test were performed to compare SSTR2
methylation levels between cancer tissues and adjacent
tissues. All the P values were adjusted by logistic regres-
sion. Multivariate Cox proportional hazard models were
used to calculate hazard ratios (HR) and the correspond-
ing 95 % confidence intervals (95 % CI). A two-tailed P
< 0.05 was considered to be significant. Figures were
drawn using GraphPad Prism 6 software (GraphPad Inc.,
San Diego, CA).
Results
In the current study, we have tested nine CpG dinucleo-
tides in the SSTR2 CpG island (CGI, chr17:71160923–
71162350) to measure SSTR2 methylation levels using
the bisulfite pyrosequencing technology (Figure 2). The
raw methylation data of nine CGs on SSTR2 gene pro-
moter were presented in Supplemental Dataset 1. Using
the mean methylation level, we preformed the associ-
ation study between 87 male tumor tissues and their ad-
jacent non-tumor tissues. In addition, the differences in
SSTR2 methylation level were not statistically associated
with age, smoking behavior, histological differentiation
or clinical stage in tumor tissues or paired tissues (all ad-
justed P > 0.05, data not shown).
Our results showed that SSTR2 promoter methylation
levels in cancer tissues were significantly higher than in
the paired non-tumor tissues (Figure 3a, 5.80 ± 3.87 %
versus 3.67 ± 3.22 %, P = 0.001, adjusted P = 0.003). Sub-
group analysis by the smoking status showed that SSTR2
promoter hypermethylation was associated with the risk
of laryngeal cancer in the patients with and without
smoking behaviors (Figure 3a, smokers: 5.46 ± 4.94 %
versus 3.88 ± 2.13 %, P = 0.013, adjusted P = 0.021; non-
smokers: 7.56 ± 5.78 versus 3.87 ± 1.87, P = 0.033, ad-
justed P = 0.033). Further subgroup analysis by age
showed that the patients aged <60 years old showed a
statistically higher methylation in cancer tissues than in
paired non-tumor tissues, but this association could not
be found in those older than 60 years old (Figure 3b,
<60y: adjusted P = 0.039; 60y~: adjusted P = 0.059; 70y~:
adjusted P = 0.287).
DNA promoter methylation is associated with clinico-
pathological characteristics, such as differentiation and
clinical stages [22, 23]. Therefore, we conducted a histo-
logical differentiation-based comparison between tumor
and non-tumor tissues. And our results showed a signifi-
cant higher methylation in the well differentiated (Fig-
ure 3C, adjusted P = 0.028) and moderately differentiated
LSCC (adjusted P = 0.037) compared with their adjacent
tissues, but the significant association was not found in
poorly differentiated LSCC compared with the controls
Fig. 2 The nine tested CpG dinucleotides in SSTR2 gene a. a: F stands for forward primer; S stands for sequencing primer; R stands for
reverse primer
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(adjusted P = 0.357). In addition, clinical stage-based
subgroup analysis showed a significant hypermethylation
in stage IV (Figure 3D, adjusted P = 0.031), but not in
other stages (stage I: adjusted P = 0.094; stage II: adjusted
P = 0.243; stage III: adjusted P = 0.221).
In order to investigate the association between SSTR2
methylation level and OS in LSCC patients, we per-
formed a multivariate Cox proportional hazard analysis
by adjusting age, stage, differentiation and smoking be-
havior. As shown in Table 1, the poor OS of LSCC pa-
tients was found to be significantly associated with
SSTR2 promoter hypermethylation (HR = 1.127, 95 % CI
= 1.034–1.228).
Discussion
Our study firstly investigated the role of SSTR2 pro-
moter methylation in the risk and progression of LSCC.
A significantly increased SSTR2 promoter methylation
was found in LSCC tissues than non-cancerous tissues.
Meanwhile, multivariate Cox analysis suggested that
SSTR2 promoter methylation was an independent prog-
nostic factor of LSCC. Our results provided a clue for
further studies on the role of SSTR2 in laryngeal carcino-
genesis, and future studies were needed to confirm its
potential as a biomarker for early diagnosis, therapy and
prognosis of laryngeal cancer.
Previous laryngeal cancer study has shown that the
overall pattern of SSTRs expression is with high levels of
SSTR1, “loss” of SSTR2 and intermediate levels of
SSTR5 [24]. For other SSTR members, there was very
little expression of SSTR3 detected in benign and pre-
malignant specimens and malignant laryngeal tumors.
Meanwhile, a variable degree of low to moderate levels
of SSTR4 expression was detected across these three
groups [12].
Fig. 3 Comparisons of mean methylation level of SSTR2 gene between tumor tissues and paired adjacent non-tumor tissues by (a) total and
smoking behavior, (b) age, (c) differentiation and (d) clinical stage a. a: T stands for tumor tissues; N stands for non-tumor tissues. P*: adjusted by
age, smoking behavior, differentiation and clinical stage
Table 1 Multivariate Cox proportional hazards analysis in 54
LSCC patients a
Characteristics N P value HR 95 % CI
Age 54 0.821 0.992 0.925–1.064
Stage
Stage I (Ref) 15 - 1.000 -
Stage II 8 0.106 6.794 0.665–69.416
Stage III 7 1.865 4.865 0.408–57.962
Stage IV 24 0.016 13.630 1.636–113.539
Differentiation
Well (Ref) 21 - 1.000 -
Moderated 21 0.706 1.267 0.370–4.344
Poorly 12 0.555 1.401 0.457–4.299
Smoking behavior
No (Ref) 7 - 1.000 -
Yes 47 0.271 2.699 0.461–15.813
SSTR2 methylation 54 0.006 1.127 1.034–1.228
a: the overall survival information of 33 LSCC patients was unavailable; Ref:
reference category; HR: hazard ratio
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DNA hypermethylation in the promoter of tumor
suppressor genes (TSGs) inhibits transcriptional initi-
ation and results in the silencing of TSGs. Hyper-
methylated promoters of tumor suppressor genes
(CHD5 [25], CHFR [26], PTEN [27], FHIT [28],
CDKN2B [29], APC [29], DAPK1 [29]) have been
shown as an important epigenetic mechanism in
LSCC. Moreover, accumulating studies have reported
other aberrantly hypermethylated genes in LSCC, in-
cluding CBY [30], IGFBP-rP1 [31], and MYCT1 [6].
Here, we provided another hypermethylated gene
(SSTR2) in LSCC. Alternation of SSTR2 promoter
methylation level in LSCC is not fully understood.
Here, we observed a significantly increased SSTR2
promoter methylation in cancerous tissues than in
their adjacent tissues, especially in the stage IV LSCC
patients. Besides, we found that SSTR2 promoter
hypermethylation could predict a poor OS of LSCC.
Taken together, these supported that the “loss” of
SSTR2 expression in laryngeal carcinoma, especially in
the late stage, might be due to a higher methylation
of SSTR2. Although mRNA levels were not deter-
mined in these specimens, our results tended to be
compatible with the previous results of the previous
laryngeal cancer study [32].
According to the Cancer Facts & Figures 2015 data
(http://www.cancer.org/research/cancerfactsstatistics/
cancerfactsfigures2015/index), most the laryngeal cancer
patients are males. In the current study, we only re-
cruited very few female samples. In order to get rid of
heterogeneity by gender, we decided to focus on the
study in males for the moment. Besides, we have per-
formed smoking status, age, histological differentiation
and stage subgroups analyses.
Age plays an important role in the carcinogenesis [33].
Interestingly, the significantly higher methylation was
found in the younger population (<60 years), which
might provide a potentially age-specific biomarker of la-
ryngeal cancer.
SSTR2 is widely expressed in normal tissues, and
it is a negative regulator of cell proliferation in hu-
man tumorigenesis [34]. Increased SSTR2 expression
led to strong up-regulation of cyclin-dependent kin-
ase inhibitor p16, which then inhibited tumor cell
cycle progression from G1 to S phase [35]. In
addition, SSTR2 deficiency may contribute to the de-
velopment of tissue invasion and metastasis process
[36]. Lower mRNA levels of SSTR2 were expressed
in the metastases from prostate cancers than in pri-
mary prostate cancers, meanwhile, decreased SSTR2
could predict poor prognosis of prostate cancer [35].
Our breakdown analysis showed a significant associ-
ation of SSTR2 methylation with LSCC risk in mod-
erately and well differentiated LSCC patients but not
in the poorly differentiated patients. Additionally,
there was a significant difference could be found in
stage IV group, even adjusted by risk factors of age
and smoking. Our results provided a hypothesis that
the SSTR2 methylation might be involved in the me-
tastasis and invasion of laryngeal cancer.
However, there were limitations in the current re-
search to be considered. Firstly, our study was involved
with 87 LSCC cancerous and 87 non-cancerous tissues.
Power analysis showed 90.8 % power for overall test and
15.1–100.0 % power for the subgroup analyses by differ-
entiation, histological stages of cancerous tissues and
age. Thus, our observations in the total samples were re-
liable, however, the negative results in the subgroup ana-
lyses might need to be confirmed with larger sample size
in the future. Secondly, the professional background was
a potential risk factor in laryngeal disease. A previous
study has reported that professional voice users such as
singers may be susceptible to laryngeal disease [37]. Un-
fortunately, we didn’t collect the professional back-
ground of patients.
Conclusions
This study indicated that SSTR2 promoter hypermethy-
lation was associated with the risk and progression of la-
ryngeal cancer in males. These findings provided clues
for further studies on the role of SSTR2 in laryngeal car-
cinogenesis and its potential as a biomarker for early
diagnosis, therapy and prognosis of laryngeal cancer.
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